Enjoy complimentary customisation on priority with our Enterprise License!
The allergy immunotherapies market size is forecast to increase by USD 1.01 billion, at a CAGR of 8.95% between 2022 and 2027. Market expansion relies on various factors. Firstly, the rising incidence of allergies underscores the demand for effective treatments and therapies, driving market growth. Additionally, recent regulatory approvals and a robust pipeline of innovative products contribute to market expansion by addressing unmet medical needs and providing new therapeutic options. Furthermore, growing market consolidation plays a significant role in shaping the competitive landscape and driving overall market growth. As companies merge or acquire smaller firms, they gain access to new technologies, resources, and markets, fostering innovation and market expansion. These factors collectively propel the growth of the market, indicating a promising trajectory for market growth in the foreseeable future.
To learn more about this report, Download Report Sample
Allergy immunotherapies are pivotal in addressing conditions explored in Allergy, Asthma & Immunology Research, offering relief beyond traditional medicines. The approach involves desensitizing the immune system to allergens, making it a promising avenue for combating not only allergies but potentially even cancer, where immune response modulation is crucial. Integration into the healthcare system facilitates accessibility to allergy shots, representing a paradigm shift in allergy treatment.
This market forecast report extensively covers market segmentation by product (SCIT and SLIT), type (allergic rhinitis, asthma, food allergy, and others), and geography (Europe, North America, Asia, and the Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the market forecasting report includes historic market data from 2017 to 2021.
The market share growth of the SCIT segment will be significant during the forecast period. Subcutaneous immunotherapy (SCIT), also known as allergy shots, is the most used type of immunotherapy for the treatment of various allergies. In SCIT, the patients receive small doses of allergen subcutaneously in the arm. Patients receive SCIT for long durations to increase their immunity. SCITs have proven to be highly efficient for the treatment of various respiratory allergies, including allergic rhinitis (hay fever) and asthma.
Get a glance at the market contribution of various segments Request a PDF Sample
The SCIT segment was valued at USD 962.10 million in 2017. Despite being highly effective for the treatment of rhinitis and conjunctivitis, the market has witnessed an increasing preference for other treatment options, such as SLIT, resulting in the erosion of market share for the SCIT segment. Also, the recent clinical trial failures of prominent late-stage pipeline molecules, namely immunotherapies from Circassia, are expected to hamper the growth prospects of this segment. In addition, the recent advances in various SLITs are also expected to hamper the market growth of the segment during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
Europe is estimated to contribute 53% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. They have witnessed notable demand in Europe, particularly in the context of allergic rhinitis and skin allergies. Food allergies represent a substantial portion of allergy illnesses, with an estimated 2%-37% of Europe's population reporting such sensitivities. Approximately 20% of this population experiences frequent food allergies. Prevalence rates for food allergies are notably high in certain European cities, including Zurich, Madrid, Lodz, Utrecht, Reykjavik, and Athens. Macroeconomic factors, such as pollution and eating habits, contribute to the rising incidence of allergy illnesses. For instance, alcohol consumption and air pollution have been linked to an increased risk of developing atopic dermatitis. The healthcare system in Europe plays a crucial role in addressing allergy-related health concerns, with medicines like oral immunotherapy and subcutaneous immunotherapy (SCIT), and sublingual immunotherapy (SLIT) being employed to manage allergic conditions. They are essential for managing various allergy-related conditions, including food allergies, atopic dermatitis, and allergic rhinitis. Pollen and respiratory system issues are also common triggers for allergic reactions. As the European population continues to grapple with these health concerns, the demand for effective allergy immunotherapies is expected to persist.
The market encompasses Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT), which are essential treatments for allergy illnesses in healthcare professionals' arsenals. SCIT, also known as allergy shots, utilizes biologics to stimulate the immune system against allergens. SLIT, represented by medications like Alustal from Stallergenes Greer and Palforzia from Aimmune Therapeutics, involves placing tablets under the tongue for absorption. The prevalence of allergies, including cancer and respiratory system-related allergies such as asthma, is a significant concern in emerging economies. Biotechnology and immunology advancements have led to personalized medicine approaches, enabling more effective treatments. Allergic reactions to pollen, air pollution, and other environmental factors continue to challenge the healthcare system, necessitating the development and availability of innovative medicines. Current Allergy and Asthma Reports suggest that both SCIT (Subcutaneous Immunotherapy) and SLIT (Sublingual Immunotherapy) are effective methods for allergy management, with the allergy shot being a commonly utilized treatment option
The increasing prevalence of allergies is one of the key factors driving the growth of the market. They represent a significant growth area within the healthcare industry, particularly for companies specializing in Allergy Immunotherapy. With the prevalence of allergies estimated to impact over 500 million people worldwide, the demand for effective treatment options is increasing. Allergy immunotherapies, which include Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT), offer promising solutions for managing allergic reactions to various triggers such as food, grass pollen, dust, and rhinitis or asthma. Key players in this market include Stallergenes Greer, Alustal, Aimmune Therapeutics, Hollister Allergy, Leti Pharma, Merck KGaA (Allergopharma), and Allergy Therapeutics. These companies are developing innovative biologics and harnessing the power of immunology and biotechnology to create personalized medicine for patients. Emerging economies are expected to contribute significantly to the growth of the market.
Healthcare professionals are increasingly recognizing the importance of early intervention and long-term management of allergies, particularly in light of the non-remissive nature of most allergies. Advancements in molecular mechanisms, biomarkers, and diagnostic tools are enabling more precise and effective allergy treatments. Oral allergy immunotherapies, such as tablets, are gaining popularity due to their convenience and ease of administration. Allergy shots, which involve desensitizing patients to allergens through regular injections, remain a common treatment option. Gene therapies are also being explored as potential solutions for allergies, particularly those related to cancer and severe allergic reactions. Physicians and healthcare systems are working together to implement precision medicine approaches, which take into account individual patient characteristics and genetic factors to optimize treatment plans. In summary, the market is poised for growth due to the increasing prevalence of allergies and the development of innovative treatment options. Companies specializing in Allergy Immunotherapy are at the forefront of this trend, leveraging biotechnology, immunology, and personalized medicine to create effective solutions for managing allergic reactions.
Technological advances is the primary trend shaping market growth. Allergy immunotherapy companies are at the forefront of addressing the challenges posed by the unclear pathogenesis and prognosis of various allergy indications. Healthcare professionals are in constant pursuit of effective diagnostic methods to accurately identify allergies in their early stages. The current diagnostic tools, including blood tests, skin tests, and patch tests, have limitations. Consequently, numerous research initiatives are underway to develop novel therapies for diagnosing allergies. Emerging economies are witnessing a growing prevalence of allergies due to changing lifestyles and environmental factors. Allergy immunotherapies, such as Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT), are gaining popularity as they offer long-term benefits in managing allergic reactions to food, grass pollen, dust, rhinitis, asthma, and conjunctivitis. Stallergenes Greer, Alustal, Aimmune Therapeutics, Hollister Allergy, Leti Pharma, Merck KGaA (Allergopharma), and Allergy Therapeutics are some of the key players in the market. They are focusing on the development of biologics, gene therapies, and personalized medicine to cater to the diverse needs of patients.
The immune system plays a crucial role in the development and progression of allergies. Understanding the molecular mechanisms and identifying biomarkers is essential for the development of diagnostic tools. Oral allergy immunotherapy in the form of tablets and allergens in asthma shots are being used to desensitize patients and improve their quality of life. Cancer and allergies share some common immune system responses. Biotechnology and immunology are paving the way for the development of innovative immunotherapies. Precision medicine and healthcare systems are collaborating to provide accurate diagnoses and effective treatments for allergic reactions. In conclusion, the market is witnessing significant advancements in the development of novel diagnostic tools and therapies. Companies are focusing on personalized medicine and precision healthcare to cater to the diverse needs of patients. The immune system's role in allergies and cancer is being explored to develop innovative treatments. The future lies in the integration of biotechnology, immunology, and healthcare systems to provide effective and personalized solutions for managing allergies. These advances are expected to lead to the identification of new allergens, which will lead to the development of better immunotherapies, thus resulting in the growth of the market during the forecast period.
One of the major challenges hampering market growth is the trial failure of various allergens. The market has witnessed very few clinical trial failures in recent years, as these studies failed to meet the primary endpoint. Many of the allergies have unknown pathogenesis, and as a result, the reason for the failure of the studies is unclear. For instance, In November 2019, ASIT biotech gp-ASIT+ failed to meet its Phase III trial primary endpoint.
The Phase III trial of gp-ASIT+, an innovative immunotherapy treatment for grass pollen allergies, which was administered only three weeks prior to the grass pollen season, involved randomized trials in 650 patients from Belgium, the Czech Republic, France, Germany, Hungary, and Poland. Similarly, in March 2019, As the Therapeutic birch pollen product failed to meet its primary endpoint in the Phase III B301 trial. All these clinical trial failures will affect the market position of the firms, which, in turn, is expected to hinder the growth of the market during the forecast period.
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Aimmune Therapeutics Inc. - The company offers allergy immunotherapies indicated for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2023 to 2027, as well as historical data from 2017 to 2021 for the following segments.
Allergy immunotherapies refer to treatments that help the body build a tolerance to allergens, reducing the severity and frequency of allergic reactions. They come in various forms, including sublingual tablets and drops, and subcutaneous injections. The market is significant, driven by the increasing prevalence of allergies worldwide. Allergen sources include pollen, dust mites, animal dander, and foods. The market for these therapies is expanding due to the growing awareness of allergies and the availability of new and effective treatments. Companies are investing in research and development to create more convenient and effective immunotherapies. The use of advanced technologies, such as biotechnology and nanotechnology, is also contributing to the growth of the market. they offer a long-term solution for managing allergies, making them a valuable treatment option for patients.
Market Scope |
|
Report Coverage |
Details |
Page number |
165 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.95% |
Market growth 2023-2027 |
USD 1.01 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
8.12 |
Regional analysis |
Europe, North America, Asia, and Rest of World (ROW) |
Performing market contribution |
Europe at 53% |
Key countries |
US, Germany, France, UK, and Japan |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Adamis Pharmaceuticals Corp., Aimmune Therapeutics Inc., ALK Abello AS, ALLERGOPHARMA GmbH and Co. KG, Allergy Therapeutics PLC, Biomay AG, DBV Technologies SA, Desentum Oy, HAL Allergy BV, Immunomic Therapeutics Inc., Jubilant Pharmova Ltd., LETI Pharma SLU, LOFARMA Spa, Merck KGaA, Novartis AG, Optum Inc., Shionogi and Co. Ltd., Stallergenes Greer Ltd., Torii Pharmaceutical Co. Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Drivers, Challenges, and Trends
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.